416 related articles for article (PubMed ID: 36525140)
1. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
2. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L
Coelho T; Ando Y; Benson MD; Berk JL; Waddington-Cruz M; Dyck PJ; Gillmore JD; Khella SL; Litchy WJ; Obici L; Monteiro C; Tai LJ; Viney NJ; Buchele G; Brambatti M; Jung SW; St L O'Dea L; Tsimikas S; Schneider E; Geary RS; Monia BP; Gertz M
Neurol Ther; 2021 Jun; 10(1):375-389. PubMed ID: 33638113
[TBL] [Abstract][Full Text] [Related]
3. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
Coelho T; Marques W; Dasgupta NR; Chao CC; Parman Y; França MC; Guo YC; Wixner J; Ro LS; Calandra CR; Kowacs PA; Berk JL; Obici L; Barroso FA; Weiler M; Conceição I; Jung SW; Buchele G; Brambatti M; Chen J; Hughes SG; Schneider E; Viney NJ; Masri A; Gertz MR; Ando Y; Gillmore JD; Khella S; Dyck PJB; Waddington Cruz M;
JAMA; 2023 Oct; 330(15):1448-1458. PubMed ID: 37768671
[TBL] [Abstract][Full Text] [Related]
4. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.
Masri A; Maurer MS; Claggett BL; Kulac I; Waddington Cruz M; Conceição I; Weiler M; Berk JL; Gertz M; Gillmore JD; Rush S; Chen J; Zhou W; Kwoh J; Duran JM; Tsimikas S; Solomon SD
J Card Fail; 2023 Dec; ():. PubMed ID: 38065307
[TBL] [Abstract][Full Text] [Related]
5. Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.
Yarlas A; Lovley A; McCausland K; Brown D; Vera-Llonch M; Conceição I; Karam C; Khella S; Obici L; Waddington-Cruz M
Neurol Ther; 2021 Dec; 10(2):865-886. PubMed ID: 34355354
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
8. Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy.
Falcão de Campos C; Conceição I
Drug Healthc Patient Saf; 2023; 15():51-62. PubMed ID: 36824481
[TBL] [Abstract][Full Text] [Related]
9. Eplontersen: First Approval.
Nie T
Drugs; 2024 Apr; 84(4):473-478. PubMed ID: 38413492
[TBL] [Abstract][Full Text] [Related]
10. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights.
Koike H; Katsuno M
Biomedicines; 2019 Feb; 7(1):. PubMed ID: 30764529
[TBL] [Abstract][Full Text] [Related]
12. Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.
Planté-Bordeneuve V; Perrain V
Expert Opin Drug Discov; 2024 Apr; 19(4):393-402. PubMed ID: 38281068
[TBL] [Abstract][Full Text] [Related]
13. [Gene therapy options for hereditary transthyretin-related amyloidosis].
Schilling M
Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
[TBL] [Abstract][Full Text] [Related]
14. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
[No Abstract] [Full Text] [Related]
15. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
[TBL] [Abstract][Full Text] [Related]
16. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.
Brannagan TH; Wang AK; Coelho T; Waddington Cruz M; Polydefkis MJ; Dyck PJ; Plante-Bordeneuve V; Berk JL; Barroso F; Merlini G; Conceição I; Hughes SG; Kwoh J; Jung SW; Guthrie S; Pollock M; Benson MD; Gertz M;
Eur J Neurol; 2020 Aug; 27(8):1374-1381. PubMed ID: 32343462
[TBL] [Abstract][Full Text] [Related]
17. Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis.
Dixon S; Kang X; Quan D
Ther Clin Risk Manag; 2023; 19():973-981. PubMed ID: 38047038
[TBL] [Abstract][Full Text] [Related]
18. Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study.
Yarlas A; Lovley A; Brown D; Kosinski M; Vera-Llonch M
J Neurol; 2022 Jan; 269(1):323-335. PubMed ID: 34125267
[TBL] [Abstract][Full Text] [Related]
19. Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Obici L; Ajroud-Driss S; Lin KP; Berk JL; Gillmore JD; Kale P; Koike H; Danese D; Aldinc E; Chen C; Vest J; Adams D;
Neurol Ther; 2023 Oct; 12(5):1759-1775. PubMed ID: 37523143
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
